Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson disease.
The dopamine turnover rate in the central nervous system (CNS) of parkinsonian patients was studied by means of the intravenous probenecid test during drug holiday (DH) and alternate day L-dopa therapy (ADDT). After L-dopa therapy was stopped, the dopamine turnover rate decreased more rapidly in patients with the marked wearing-off phenomenon than that in patients without fluctuation of symptoms. The lumbar CSF concentrations of L-dopa and 3-O-methyldopa of patients with and without wearing-off phenomenon were similar during L-dopa therapy. DH improved the effect of L-dopa on parkinsonian symptoms; it did not affect, however, the metabolism of exogenous L-dopa. The dopamine turnover rate in the CNS before L-dopa therapy or on on-days did not differ between patients tolerating and those not tolerating ADDT. However, it was significantly lower on off-days in patients not tolerating ADDT than in those tolerating ADDT. The relationship between dopamine storage in the CNS and the response to L-dopa therapy is discussed.
D000328:Adult; D000368:Aged; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002230:Carbidopa / Q000378:metabolism / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006207:Half-Life; D006801:Humans; D007980:Levodopa / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011339:Probenecid
D007980:Levodopa; D002230:Carbidopa; D011339:Probenecid; D004298:Dopamine